Overview of Actilyse

This section provides a clear, high-level overview of Actilyse, defining its fundamental identity, composition, and general therapeutic purpose.

Property	Description
Active ingredient	Alteplase (recombinant tissue plasminogen activator, rt-PA)
Form	Lyophilized powder and solvent for solution for injection
Pharmacological class	Thrombolytics / Fibrinolytic agents
General Purpose	Rapidly dissolving pre-existing blood clots
Origin	Biosynthetic (recombinant DNA technology)

Actilyse: Definition and Pharmacological Class

Actilyse is a prescription-only medication whose active ingredient is Alteplase, an agent classified as a thrombolytic or fibrinolytic agent. This pharmacological classification means its primary action involves breaking down the fibrin structures that stabilize blood clots. Alteplase is a complex, purified glycoprotein designed to be structurally identical to the body's natural tissue plasminogen activator (t-PA). It is a biosynthetic substance, specifically manufactured using recombinant DNA technology, a method that supports its consistency and purity. Actilyse is clinically recognized for its role in addressing vascular blockages where rapid clot dissolution is necessary.

Composition and Physical Form

The medicine is supplied as a lyophilized powder and solvent system, a specialized formulation that ensures the stability of the active Alteplase protein until the moment of use. The powder contains the active ingredient, and the solvent is sterile water for injections. The final solution is administered exclusively via the intravenous (IV) route. This IV administration route allows for rapid action throughout the circulatory system.

General Purpose as a Clot Dissolver

The overall therapeutic purpose of Actilyse is to act as a potent clot dissolver, achieving the rapid lysis of existing blood clots within the circulation. Alteplase works by engaging the natural process of fibrinolysis, ultimately removing the physical obstruction within a blood vessel. By breaking down the fibrin mesh, the medicine helps to restore normal blood flow to organs and tissues compromised by vascular blockage. The ability of Alteplase to quickly restore the blocked vessel’s patency is essential for addressing acute circulatory events.

Regulatory References

Alteplase Administration and IV Route (NCBI/NIH)

What side effects are possible with Actilyse?

Possible Side Effects and Safety Information: Actilyse

The safety profile of Actilyse (Alteplase) is defined by its action as a thrombolytic agent, with the most frequent and significant adverse reaction being hemorrhage (bleeding), as documented in official regulatory labeling. This risk encompasses various forms of bleeding, including potentially life-threatening events.

Official Adverse Reaction Classification

The most frequent adverse reaction consistently noted across regulatory documents is hemorrhage. Frequency classifications may vary slightly by region, but serious adverse events are universally highlighted.

Classification	Representative Adverse Reaction Class
Very Common	Hemorrhage (e.g., hematoma, site-specific bleeding)
Uncommon	Reperfusion Arrhythmias, Pulmonary Hemorrhage
Rare	Serious Hypersensitivity (Anaphylaxis), Cholesterol Embolization Syndrome

System-Organ Class and Serious Reactions

Adverse events are often grouped by the physiological system affected. Key systems involved include Vascular Disorders (bleeding), Nervous System Disorders (including Intracerebral Hemorrhage), and Cardiac Disorders (e.g., reperfusion phenomena, reinfarction).

Serious Adverse Reactions explicitly documented in official labeling include Intracerebral Hemorrhage, which represents the major adverse reaction in the treatment of acute ischemic stroke, and Cholesterol Embolization Syndrome, which has been reported rarely and can sometimes be fatal. Hypersensitivity reactions, including orolingual angioedema, are also noted as potentially serious events.

Safety Considerations and Restrictions

Official safety information addresses specific contexts and populations. The risk of stroke and mortality is generally noted to increase in advanced age (e.g., patients over 75 years). Safety is also constrained by concomitant drug use: the risk of orolingual angioedema may be increased with co-administration of ACE inhibitors, and the overall risk of bleeding is increased with anticoagulants or antiplatelet agents.

Regulatory documents also note time-related patterns, such as the observation of angioedema during and up to 2 hours after infusion. Coagulation tests are noted to be unreliable during the therapy period unless specific precautions are taken.

Overdose and Emergency Response

Overdose and When to Seek Help

The Actilyse (Alteplase) overdose profile is defined by the single critical risk of uncontrolled hemorrhage, which is the primary documented clinical manifestation of overexposure. The medication is only administered under direct medical supervision, and the risk of severe adverse outcomes increases with doses exceeding the recommended limits.

Overdose Manifestations and Severe Outcomes

The predominant signs of overdose involve bleeding, which may be internal or external, frequently occurring at arterial and venous puncture sites. Overdose may lead to serious and potentially fatal hemorrhage, with Intracranial Hemorrhage (ICH) being a specifically documented severe outcome. The physiological systems most affected are the cardiovascular and central nervous systems due to blood loss and the risk of ICH.

Official Emergency Actions

Since no specific antidote is known for Alteplase, the regulatory management strategy is entirely focused on controlling the bleeding. If serious bleeding is observed, the Actilyse infusion must be immediately terminated. Treatment is strictly symptomatic and supportive and may include measures such as administering cryoprecipitate (to restore fibrinogen), fresh frozen plasma, or platelets. Immediate emergency medical care is required in all instances of suspected overdose or uncontrolled, serious bleeding.

Therapeutic Uses of Actilyse

Immediate Management of Acute Life-Threatening Blood Clots

Actilyse (Alteplase) is commonly used in clinical settings that involve acute or unstable symptom patterns related to blockages in the circulatory system. This is relevant for conditions associated with acute or disruptive episodes, such as acute ischemic stroke, acute myocardial infarction (heart attack), and massive pulmonary embolism. The primary therapeutic purpose of the medication is to ease symptoms linked to organ-specific functional stress. It is applied in addressing symptoms related to acute neurological or muscular activity, such as sudden neurological deficits, acute persistent chest pain, or profound shortness of breath and circulatory collapse. This approach may assist with maintaining functional stability and contributes to easing the overall symptom load.

Specialized Use for Clearing Blocked Medical Devices

Beyond its use in acute therapeutic contexts, Actilyse is commonly used to address localized symptoms related to clot-related blockages in specialized venous access devices (catheters). This application is relevant for managing symptoms related to organ-specific functional stress in the access device context. The benefit to the patient supports general well-being during symptomatic phases and assists with maintaining functional stability.

Quick Fact: Support for Acute Symptomatic Episodes

Actilyse is applied in situations where symptoms create noticeable physiological strain and may assist with maintaining functional stability during periods of acute or disruptive episodes.

Regulatory References

NIH MedlinePlus overview on Alteplase

Eligibility and Restrictions for Use

The eligibility for Actilyse is strictly determined by government regulatory bodies (e.g., FDA, EMA) to manage the risk of bleeding associated with this medicine. Actilyse is generally approved for use in adult patients for its major acute indications.

Eligibility Scope

Classification	Who is Included/Excluded (Regulatory Basis)
Populations for whom use is allowed	Adult patients for acute ischemic stroke (AIS), acute myocardial infarction (AMI), acute massive pulmonary embolism (PE), and catheter occlusion. Also approved for pediatric use in catheter occlusion.
Populations for whom use is contraindicated	Patients with active internal bleeding, any history of intracranial hemorrhage, recent major surgery or trauma, or current severe uncontrolled hypertension. Contraindicated if receiving effective oral anticoagulant treatment (e.g., INR > 1.7 for some uses).
Age-related Eligibility Rules	For major acute indications (AIS/AMI/PE), safety and effectiveness are not established in pediatric patients. Use in older adults (e.g., over 75 years for AIS) requires caution due to a documented increased risk of bleeding.

Eligibility-Related Restrictions

The medicine is restricted by certain clinical factors. For AIS, treatment must be initiated within a narrow time window (e.g., 3 to 4.5 hours from symptom onset, depending on the region/label). Use is also conditional on the patient not having conditions like severe liver disease, infectious endocarditis, or a documented low platelet count.

Pregnancy and Lactation

Official labeling advises that the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown if Alteplase is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Actilyse (Alteplase) as defined by government regulatory authorities.

Combinations Officially Contraindicated

Regulatory labeling designates certain drug combinations as contraindicated due to a high risk of adverse outcomes:

Defibrotide and Prothrombin Complex Concentrate, Human are strictly prohibited due to pharmacodynamic synergism, which increases the risk of bleeding.
Oral Anticoagulants (such as Warfarin) are contraindicated in patients already receiving effective anticoagulant treatment, specifically when the International Normalized Ratio (INR) is greater than 1.3.

Pharmacodynamic Reinforcement

The most significant class of documented interactions involves agents that compound the bleeding risk through their effects on coagulation or platelet function:

Product Category	Documented Interaction
Anticoagulants (e.g., Heparin)	Increased risk of haemorrhage/bleeding
Platelet Aggregation Inhibitors (e.g., Aspirin, Clopidogrel)	Increased risk of haemorrhage/bleeding
ACE Inhibitors	Potential increased risk of orolingual angioedema

Procedural and Timing Restrictions

Actilyse administration is subject to specific regulatory constraints regarding co-administration and the timing of adjunctive therapies:

Infusion Compatibility: Actilyse must not be mixed with any other medicinal product in the same infusion vial or venous line, including Heparin.
Acute Ischemic Stroke: Intravenous Heparin and platelet aggregation inhibitors are documented to be avoided during the first 24 hours following Actilyse treatment for this specific indication to manage haemorrhagic risk.

No interactions involving specific metabolic pathways (such as CYP enzymes or drug transporters) that alter the plasma exposure of Alteplase are explicitly documented in regulatory product information.

Mechanism of Action

How Actilyse Works: Mechanism of Action

Actilyse (Alteplase) functions as a proteolytic enzyme that directly engages the body's natural clot-dissolving pathway, known as fibrinolysis. Its primary molecular target is the inactive precursor protein Plasminogen, which it converts into the active enzyme, Plasmin. The enzyme exhibits high fibrin specificity; its catalytic activity is significantly amplified when it is bound to the Fibrin meshwork of a thrombus, localizing the activation of the cascade to the site of the obstruction.

Once activated, Plasmin initiates the systematic degradation of the clot's structure. Plasmin hydrolyzes the peptide bonds within the cross-linked Fibrin polymers, physically breaking down the insoluble meshwork into soluble fragments known as Fibrin Degradation Products (FDPs). The primary physiological change resulting from this action is thrombus lysis (clot dissolution), which is the physical removal of the obstruction.

The lytic mechanism is subject to inactivation by physiological components within the circulation. The primary constraint involves endogenous inhibitors, such as Plasminogen Activator Inhibitor 1 (PAI-1), which rapidly forms a stable, non-functional complex with Alteplase. These inhibitory mechanisms restrict the duration and extent of the enzymatic activity.

Dosage and Administration Information

How Actilyse is Used — Administration Guidelines

Actilyse (Alteplase) is used under strict protocols for time-critical acute conditions and specific medical device clearance. The administration route is determined by the intended therapeutic goal, leading to two distinct methods: Intravenous (IV) Infusion for acute systemic conditions and Intracatheter Instillation for localized clearing of blocked central venous access devices (CVADs).

Administration Scope and Dosing

Systemic administration, such as for acute ischemic stroke, requires a weight-based dose of 0.9 mg/kg up to a maximum of 90 mg. This total dose is typically administered over 60 minutes, starting with an initial 10% bolus over the first minute. For massive pulmonary embolism, the standard adult dose is 100 mg delivered over a total of 2 hours. All systemic use occurs as a single, acute intervention and is critically time-dependent, requiring initiation within the established therapeutic window of symptom onset.

Preparation and Special Conditions

Actilyse is supplied as a lyophilized powder that must be reconstituted with Sterile Water for Injection to a specified concentration, usually 1 mg/mL. The solution must be prepared using gentle swirling; excessive shaking is strictly prohibited as it can compromise the active substance. The solution should not be mixed with any other medications in the same IV line. For CVAD clearance, the fixed 2 mg dose is instilled and allowed to dwell for a prescribed time before function is reassessed, with a second dose considered only if the first attempt fails to restore patency. Dosage for CVAD clearance in patients under 30 kg is adjusted volumetrically, limited by the 2 mg maximum dose. This procedural structure ensures the drug is delivered correctly under highly controlled clinical conditions.

Recent Clinical Evidence

Actilyse: Recent Clinical Evidence

Evidence for Use in Acute Ischemic Stroke (AIS)

Research examined the medicine's application in Acute Ischemic Stroke (AIS). The primary evidence was derived from large Randomized Controlled Trials (RCTs) and meta-analyses comparing the medicine to a placebo in adult patients. Studies primarily focused on measuring functional independence at 90 days and tracking survival.

Findings describe patterns observed in the studies related to measured functional outcomes. Studies consistently monitored the occurrence of symptomatic intracranial hemorrhage (bleeding in the brain) as a key outcome. Studies explored the concept of time dependency, noting that the measured functional outcomes apply only to the populations studied within specific, short time windows.

Evidence for Use in Acute Myocardial Infarction (AMI)

Actilyse was evaluated in patients experiencing a heart attack (AMI). The evidence was derived from large-scale Randomized Controlled Trials (RCTs) that compared the medicine against placebo or other agents. Studies primarily monitored survival/mortality (e.g., 30-day mortality) and the restoration of coronary blood flow.

Pivotal trials data show patterns related to measured 30-day survival. Research consistently monitored the occurrence of major bleeding and stroke as recorded outcomes. The current research context is continuously evaluated due to the emergence of other revascularization techniques.

Evidence for Use in Acute Massive Pulmonary Embolism (PE)

The medicine was studied for use in patients with a massive pulmonary embolism (PE). The evidence was observed in Randomized Controlled Trials (RCTs) primarily focused on high-risk adult patients exhibiting signs of severe hemodynamic compromise or right ventricular strain. The sample sizes were modest for this specific condition, and the evidence is primarily focused on severe, high-risk PE.

Evidence for Clearing Occluded Central Venous Access Devices

Actilyse was evaluated in patients with clot-related blockages in indwelling catheters, with studies involving both adult and pediatric patients. The primary outcome measured was the restoration of catheter function/patency. Trials data show patterns related to a significantly higher rate of function restoration after the use of the medicine compared to a placebo. Comparative evidence is lacking versus other non-pharmacological catheter patency interventions.

Long-term Studies and Follow-up Durations

Follow-up durations were limited in many pivotal trials, with primary outcomes often assessed at 30 or 90 days. Extended follow-up data (e.g., beyond 6 months) for the acute indications are not fully established, and information may be limited to subsequent observational registries.

Evidence in Specific Patient Groups

Studies explored the medicine's use in certain specific groups, including older adults and pediatric patients (for catheter clearance). Data for certain groups remain insufficient, especially for pregnant populations. Evidence quality varies across studies for subgroups, as the number of individuals studied in these analyses was limited.

What is Still Uncertain About Actilyse

Research provides context but not individual predictions. Findings describe group patterns, not personal outcomes. There are several areas where certainty remains low, including whether long-term effects are fully established regarding functional status beyond the standard follow-up periods.

Frequently Asked Questions (FAQ)

Common questions about Actilyse (FAQ)

Q: What are the risks of bleeding mentioned in the official warnings for Actilyse?

Official regulatory warnings state that the most common and significant risk is hemorrhage, or bleeding. This risk includes external bleeding, such as at the injection or puncture site, and internal bleeding, which can occur in the stomach, intestines, or even the head (intracranial hemorrhage).

Q: Can Actilyse cause an allergic reaction, and what are the signs to watch for?

Yes, official product information reports that hypersensitivity reactions, including rare cases of a serious reaction called anaphylaxis, have occurred. Staff will monitor for signs such as rash, itching, hives, or swelling of the face, tongue, or throat (angioedema), which can indicate an allergic response.

Q: What kind of studies have been done to confirm the effects of Actilyse?

The understanding of this medicine's effects is based on extensive clinical research, primarily large-scale randomized controlled trials (RCTs). These studies compare the medicine to a placebo or other treatments to measure specific outcomes like the patient's functional independence, overall survival, and how quickly blood flow is restored to the blocked vessel.

Q: Why is Actilyse not typically given if a patient has very mild stroke symptoms?

Regulatory-based treatment criteria for stroke often restrict use to patients whose symptoms are considered disabling. This is generally due to official criteria designed to ensure the risk of bleeding complications does not outweigh the potential benefits, which may be marginal in very mild cases.

Q: What specific warnings exist for using Actilyse in the elderly population?

Official information notes that patients of advanced age (e.g., over 80 years) may face a higher absolute risk of adverse outcomes, including bleeding in the brain. Official documentation states that for older adults, the decision for treatment involves weighing the potential benefits against the increased bleeding risks documented in regulatory materials.

Q: Is Actilyse safe to use during pregnancy or while breastfeeding?

Official labeling advises that the medicine should only be used during pregnancy if the potential benefit to the patient is judged to outweigh the potential risk to the fetus. It is unknown if the active ingredient passes into human milk, so caution is generally advised for patients who are breastfeeding.

Q: What is the general recommendation regarding physical activity after Actilyse treatment?

Official regulatory warnings indicate that, due to the heightened risk of bleeding after treatment, precautions should be taken to limit physical activity and avoid trauma or injury. Healthcare staff will monitor for bleeding or bruising.

Q: How long does the drug stay in the body after the infusion is finished?

The active substance is eliminated very quickly. According to official pharmacokinetic data, approximately half of the drug is cleared from the bloodstream within about five minutes after the end of the infusion. This rapid clearance reflects the fact that the duration and extent of its enzymatic activity are physiologically restricted.

Q: What are the most common safety concerns or risks associated with Actilyse?

The most significant and frequent risk documented in regulatory summaries is hemorrhage (bleeding). Beyond bleeding, other common adverse effects officially listed in product information include a temporary drop in blood pressure (hypotension), nausea, and vomiting.

Q: How quickly does Actilyse start working after it is given?

The administration method is designed to initiate the drug's effect immediately. The treatment protocol is started with a rapid first injection (bolus) followed by a continuous infusion, confirming that the initiation of the drug's effect begins as soon as it enters the bloodstream to start dissolving the clot.

Q: Why is there a time limit for when Actilyse can be used for stroke symptoms?

The strict time limit is based on clinical evidence showing that the treatment is strongly time-dependent. The limit is established because, beyond the approved window, official evidence indicates the balance of benefit versus the risk of bleeding complications becomes unfavorable.

Q: What is the difference between Actilyse and other clot-dissolving drugs like Tenecteplase?

Actilyse's active ingredient is alteplase (rt-PA). While it belongs to the same class of clot-dissolving drugs, the main difference lies in its exact molecular structure, administration method (Actilyse requires a slower infusion, while others may be a rapid single injection), and specific approved uses. Official regulatory labels do not make comparative claims about the effectiveness or safety versus other medicines.

Q: Can Actilyse be used in children or adolescents?

Actilyse is not approved for major acute indications like heart attack or stroke in children or adolescents under 18 because safety and effectiveness have not been established. However, a specific formulation is officially approved for use in both adults and pediatric patients to clear blood clots blocking central venous access devices (catheters).

Q: Is there an increased risk of bleeding from puncture sites after receiving Actilyse?

Yes, official warnings explicitly state that the medicine can cause bleeding at both arterial and venous puncture sites. As a result, staff are instructed to carefully monitor and minimize procedures, such as avoiding injections where possible, to manage this specific risk.

Q: Are there any known interactions between Actilyse and alcohol?

Official government-issued patient resources generally caution against excessive alcohol intake during treatment. This is due to concerns that alcohol may irritate the stomach and could potentially increase the overall risk of bleeding when combined with a potent clot-dissolving medicine.

Q: What is the official information regarding the use of Actilyse in patients with liver disease?

Official regulatory documents list severe liver disease as a contraindication—a condition that prohibits the use of the drug. The liver is vital for producing clotting factors, and severe impairment significantly increases the risk of serious, uncontrolled hemorrhage.

Q: What is the risk of a blood clot migrating after Actilyse treatment?

Official warnings note a risk of thromboembolism (a clot moving). Specifically, the medicine may increase the risk of a clot fragment breaking off and moving elsewhere (re-embolization) in patients who are known to have a clot in the left side of their heart, often due to certain underlying heart conditions.

Q: What are the recommendations for monitoring blood sugar levels during Actilyse therapy?

Monitoring a patient's blood glucose (sugar) level is a required part of the treatment protocol for conditions like acute ischemic stroke. Official information states that extreme blood sugar levels, both very high or very low, must be checked and managed as they can affect eligibility and outcomes of the treatment.

How should Actilyse be stored and disposed of?

Official Storage and Disposal Requirements for Actilyse (Alteplase)

Component	Mandatory Storage Conditions
Dry Powder	Store refrigerated between 2 C and 8 C (36 F and 46 F).
Reconstituted Solution	Chemically stable for 24 hours when refrigerated (2 C to 8 C) or 8 hours at 25 C (77 F), but immediate use is preferred.

Handling and Preparation:

Actilyse must be reconstituted with the provided solvent under aseptic conditions. The vial should be swirled gently, not shaken, to avoid foaming. The solution must be visually inspected for particulate matter and discoloration before use.

Disposal:

Any unused or expired Actilyse product, including remaining reconstituted solution, must be disposed of according to institutional, local, or national pharmaceutical waste regulations. Disposal typically involves drug take-back programs or authorized collection sites to ensure safe environmental handling.

Actilyse